U.S. Markets closed

AbbVie Several Candidates to Replace Humira in the Pipeline

NEW YORK, NY / ACCESSWIRE / July 25th, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on AbbVie Inc. (ABBV), a research-based pharmaceutical company. AbbVie is engaged in the discovery, development, manufacturing, and sale of a variety of pharmaceutical products.

AbbVie has a dominant product in Humira that is likely to continue its growth trajectory. It accounts for more than 60 percent of the company's revenue. Humira is one of the best-selling drugs in the world by a significant margin. It is a biologic therapy administered as a subcutaneous injection for the treatment of (among other things) rheumatoid arthritis, psoriatic arthritis, Crohn's disease, plaque psoriasis, ulcerative colitis, and other autoimmune diseases. While AbbVie faces significant potential competition from manufacturers of biosimilar products, the company believes that it can enforce its intellectual property rights until 2022.

Get a Q1 review, an analysts outlook, and a look at AbbVie's pipeline in this report with no obligation READ MORE

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/abbvie/

AbbVie's pipeline consists of more than 50 compounds or indications in clinical development individually or under collaboration / licensing agreements. More than half of these programs are in mid or late-stage development. At a recent healthcare conference hosted by Deutsche Bank, AbbVie CFO Bill Chase stated that the company expects to have 20 new assets in place by 2020.

AbbVie is scheduled to report on several clinical studies in the next two quarters, and the results could provide an immediate boost to its share price.

Read about the importance of AbbVie's pipeline to their future in our full report READ MORE

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/abbvie/

DISCLOSURE

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Ivan Neilson, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source